Last reviewed · How we verify
NCT05071196
Facilitated Vegan Diet on Cardiometabolic Endpoints and Trimethylamine N-oxide
NA trial testing Facilitated Vegan Diet in Cardiometabolic Risk Factors in 70 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | David Grant U.S. Air Force Medical Center |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 70 |
| Start date | 1 January 2022 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Facilitated Vegan Diet
- Omnivorous Diet
Conditions studied
- Cardiometabolic Risk Factors — all drugs for Cardiometabolic Risk Factors →
Sponsor
David Grant U.S. Air Force Medical Center
Who can join
18 and older, any sex, with Cardiometabolic Risk Factors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Vegan meal kit delivery offers consumer convenience and has shown benefit in cardiometabolic parameters such as low-density lipoprotein cholesterol (LDL-c) and weight. The purpose of this study is to evaluate the impact of meal kit facilitated vegan diet on LDL-c and trimethylamine N-oxide (TMAO) when compared to an omnivorous diet control.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05071196
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiometabolic Risk Factors
Currently open trials in the same condition.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07363616 — Pilot Test of Five Weight Neutral Interventions to Improve Health Among Adults of Higher Body Weight · NA · recruiting
- NCT07053657 — Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight/Obesity Adolescents in China · NA · recruiting
- NCT07513168 — Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults · Phase 4 · recruiting
- NCT06775132 — Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes · recruiting
Other David Grant U.S. Air Force Medical Center trials
Trials by the same sponsor.
- NCT06955923 — Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty · Phase 2 · completed
- NCT06911359 — The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis · Phase 2 · recruiting
- NCT04604145 — Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR · NA · completed
- NCT04646642 — Psychological Health, Coping Strategies and Preferences of Military COVID-19 Deployers · completed
- NCT04451070 — Impact of Curricular Transformation on Family Medicine Resident Burnout · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05071196 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by David Grant U.S. Air Force Medical Center
- Last refreshed: 1 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05071196.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing